Recipient and allograft characteristics by preimplant biopsy-reported ATN
| Characteristic | All (N=651) | ATN (n=110) | No ATN (n=541) | P Valuea |
|---|---|---|---|---|
| Recipient | ||||
| Age, yr | 59 (51–67) | 60 (50–67) | 59 (51–67) | 0.9 |
| Men | 407 (63) | 71 (65) | 336 (62) | 0.63 |
| Body mass index, kg/m2 | 28 (25–33) | 29 (25–33) | 28 (25–32) | 0.32 |
| Black race | 268 (41) | 42 (38) | 226 (42) | 0.49 |
| Dialysis duration, mo | 52 (31–71) | 49 (35–69) | 52 (31–72) | 0.97 |
| Cause of ESRD | 0.09 | |||
| Hypertension | 211 (32) | 25 (23) | 186 (34) | |
| Diabetes | 194 (30) | 38 (35) | 156 (29) | |
| GN | 94 (14) | 21 (19) | 73 (13) | |
| Graft failure (prior transplant) | 40 (6) | 9 (8) | 31 (6) | |
| Other | 112 (17) | 17 (15) | 95 (18) | |
| HLA mismatches | 5 (4–5) | 5 (4–6) | 5 (4–5) | 0.04 |
| HLA-DR mismatches | 0.04 | |||
| 0 | 86 (13) | 16 (15) | 70 (13) | |
| 1 | 278 (43) | 35 (32) | 243 (45) | |
| 2 | 286 (44) | 59 (54) | 227 (42) | |
| Allograft (donor) | ||||
| Age, yr | 51 (44–58) | 53 (47–60) | 51 (43–58) | 0.44 |
| Men | 407 (63) | 62 (56) | 345 (64) | 0.14 |
| Body mass index, kg/m2 | 28 (24–33) | 28 (24–34) | 28 (24–33) | 0.73 |
| Black race | 117 (18) | 13 (12) | 104 (19) | 0.23 |
| Hypertension | 338 (52) | 48 (44) | 290 (54) | 0.06 |
| Diabetes | 109 (17) | 16 (15) | 93 (17) | 0.5 |
| Cause of death | 0.16 | |||
| Head trauma | 126 (19) | 22 (20) | 104 (19) | |
| Stroke | 290 (45) | 46 (42) | 244 (45) | |
| Anoxia | 216 (33) | 42 (38) | 174 (32) | |
| Other | 126 (19) | 22 (20) | 104 (19) | |
| Hepatitis C | 13 (2) | 2 (2) | 11 (2) | 0.88 |
| Expanded-criteria donor | 243 (37) | 43 (39) | 200 (37) | 0.67 |
| Donation after cardiac death | 154 (24) | 22 (20) | 132 (24) | 0.32 |
| Kidney donor risk index | 1.44 (1.23–1.67) | 1.43 (1.23–1.59) | 1.45 (1.21–1.69) | 0.28 |
| Kidney donor profile index, % | 84 (70–92) | 83 (71–89) | 84 (69–92) | 0.27 |
| Admission serum creatinine, mg/dl | 1.0 (0.8–1.3) | 1.0 (0.8–1.3) | 1.0 (0.7–1.2) | 0.37 |
| Terminal serum creatinine, mg/dl | 1.0 (0.7–1.4) | 1.0 (0.7–1.4) | 1.0 (0.7–1.4) | 0.91 |
| Terminal urine output, ml/h | 129 (88–218) | 130 (87–219) | 126 (97–196) | 0.60 |
| Any vasoactive agent usedb | 550 (84) | 460 (85) | 90 (82) | 0.40 |
| Cold-ischemia time, h | 17 (13–22) | 16 (12–23) | 17 (13–22) | 0.53 |
| Kidney machine perfused | 433 (67) | 81 (74) | 352 (65) | 0.09 |
| Perfusate flow at 4 h, ml/min | 115 (96–130.5) | 116 (96–131) | 109 (96–129) | 0.28 |
| Renal resistance at 4 h, mmHg/ml per min | 0.23 (0.19–0.29) | 0.23 (0.18–0.29) | 0.25 (0.2–0.3) | 0.16 |
Values are the median (interquartile range) or n (%). ATN, acute tubular necrosis.
↵a P values comparing kidneys with to those without ATN by t tests for continuous variables or chi-squared tests for categorical variables.
↵b Considered “yes” if at least one of the following medications were administered as part of deceased-donor management within 24 hours of organ procurement: dopamine, epinephrine, norepinephrine, phenylephrine, arginine vasopressin, dobutamine, or sodium nitroprusside.